MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

ALN

A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of ‘abusing’ the patent system to send prices higher, Bloomberg reported on Thursday.

The drugmakers have been accused of making sham patents to send prices higher and clip the wings of competition, the news agency reported, citing letters from Democrats Elizabeth Warren and Pramila Jayapal.

Astra’s Symbicort asthma treatment and GSK’s Advair and Flovent pair of inhalers are among the products mentioned in a letter sent by Warren to the drugmakers.

https://www.bloomberg.com/news/articles/2023-12-14/astra-abbvie-slammed-by-warren-for-abusing-drug-patent-system

AstraZeneca shares were 2.6% lower at 10,193.58 pence each late Friday in London. GSK was down 2.8% at 1,420.40p. AbbVie was down 0.3% at $154.55 in New York.

Copyright 2023 Alliance News Ltd. All Rights Reserved.